CN104321345B - 用于癌症诊断的针对密蛋白18.2的抗体 - Google Patents
用于癌症诊断的针对密蛋白18.2的抗体 Download PDFInfo
- Publication number
- CN104321345B CN104321345B CN201380024247.0A CN201380024247A CN104321345B CN 104321345 B CN104321345 B CN 104321345B CN 201380024247 A CN201380024247 A CN 201380024247A CN 104321345 B CN104321345 B CN 104321345B
- Authority
- CN
- China
- Prior art keywords
- antibody
- cell
- cancer
- amino acid
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Description
Claims (8)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810016956.9A CN108047331B (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN202210243984.0A CN114573697A (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2012/001991 | 2012-05-09 | ||
PCT/EP2012/001991 WO2013167153A1 (en) | 2012-05-09 | 2012-05-09 | Antibodies useful in cancer diagnosis |
PCT/EP2013/001331 WO2013167259A1 (en) | 2012-05-09 | 2013-05-06 | Antibodies against claudin 18.2 useful in cancer diagnosis |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810016956.9A Division CN108047331B (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN202210243984.0A Division CN114573697A (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104321345A CN104321345A (zh) | 2015-01-28 |
CN104321345B true CN104321345B (zh) | 2018-03-30 |
Family
ID=48407427
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210243984.0A Pending CN114573697A (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN201810016956.9A Active CN108047331B (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN201380024247.0A Active CN104321345B (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210243984.0A Pending CN114573697A (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN201810016956.9A Active CN108047331B (zh) | 2012-05-09 | 2013-05-06 | 用于癌症诊断的针对密蛋白18.2的抗体 |
Country Status (28)
Country | Link |
---|---|
US (3) | US9512232B2 (zh) |
EP (3) | EP4036119A1 (zh) |
JP (5) | JP6232646B2 (zh) |
KR (3) | KR20230035697A (zh) |
CN (3) | CN114573697A (zh) |
AR (1) | AR090973A1 (zh) |
AU (3) | AU2013258432B2 (zh) |
BR (1) | BR112014026755B8 (zh) |
CA (1) | CA2869725C (zh) |
CY (1) | CY1122676T1 (zh) |
DK (1) | DK2847225T3 (zh) |
ES (1) | ES2763965T3 (zh) |
HK (1) | HK1202557A1 (zh) |
HR (1) | HRP20192347T1 (zh) |
HU (1) | HUE049171T2 (zh) |
IL (1) | IL235261B (zh) |
LT (1) | LT2847225T (zh) |
MX (1) | MX369740B (zh) |
NZ (2) | NZ700823A (zh) |
PL (1) | PL2847225T3 (zh) |
PT (1) | PT2847225T (zh) |
RS (1) | RS59868B1 (zh) |
RU (1) | RU2661772C2 (zh) |
SG (2) | SG11201406472WA (zh) |
SI (1) | SI2847225T1 (zh) |
UA (2) | UA123943C2 (zh) |
WO (2) | WO2013167153A1 (zh) |
ZA (1) | ZA201407336B (zh) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
US10093736B2 (en) | 2012-11-13 | 2018-10-09 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
KR102046110B1 (ko) * | 2015-12-04 | 2019-11-18 | 주식회사 엘지화학 | 유무기 혼합 페로브스카이트, 이의 제조 방법 및 이를 포함하는 태양 전지 |
BR112019000327A8 (pt) | 2016-07-08 | 2022-10-18 | Carsgen Therapeutics Co Ltd | Anticorpo para anticlaudina 18a2 e uso do mesmo |
KR20200129116A (ko) * | 2018-03-08 | 2020-11-17 | 페인스 테라퓨틱스 인코포레이티드 | 항-클라우딘 18.2 항체 및 이의 용도 |
RU2020128013A (ru) | 2018-03-14 | 2022-04-15 | Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. | Антитела против клаудина 18.2 |
SG10202111141WA (en) * | 2018-05-18 | 2021-11-29 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
JP7468903B2 (ja) * | 2018-06-17 | 2024-04-16 | エルアンドエル バイオファーマ カンパニー リミテッド | Cldn18.2を標的とする抗体、二重特異性抗体、adc及びcarならびにその使用 |
CN110606891B (zh) * | 2018-06-17 | 2022-12-06 | 上海健信生物医药科技有限公司 | 一种针对人cldn18.2的抗体分子,抗原结合片段及其医药用途 |
WO2020018852A2 (en) * | 2018-07-18 | 2020-01-23 | Askgene Pharma Inc. | Novel antibodies and methods for making and using the same |
KR20210042117A (ko) * | 2018-08-03 | 2021-04-16 | 암젠 리서치 (뮌헨) 게엠베하 | Cldn18.2 및 cd3에 대한 항체 작제물 |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
WO2020038404A1 (zh) * | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
KR20210050547A (ko) * | 2018-08-27 | 2021-05-07 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 항-클라우딘18.2 항체 및 이의 용도 |
JP2022511394A (ja) * | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Cldn18の抗体及び化学療法薬の併用療法 |
WO2020082209A1 (zh) * | 2018-10-22 | 2020-04-30 | 上海吉倍生物技术有限公司 | 抗cldn18.2抗体及其用途 |
BR112021011014A2 (pt) * | 2018-12-07 | 2021-08-31 | Zlip Holding Limited | Anticorpos anti-claudina e usos destes |
CN113166246A (zh) * | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
JP2022516505A (ja) * | 2018-12-28 | 2022-02-28 | スパークス・セラピューティクス・インコーポレイテッド | 癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法 |
CN116333141A (zh) * | 2019-01-15 | 2023-06-27 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
KR20210134321A (ko) | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | 항-클라우딘 18 항체 및 이의 이용 방법 |
KR20210148216A (ko) * | 2019-04-01 | 2021-12-07 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-클라우딘 18.2 항체 및 이의 응용 |
JP2022529703A (ja) * | 2019-04-19 | 2022-06-23 | 康▲諾▼▲亞▼生物医葯科技(成都)有限公司 | 腫瘍治療薬及びその応用 |
KR20220024010A (ko) * | 2019-05-16 | 2022-03-03 | 치루 파머수티컬 컴퍼니 리미티드 | 클라우딘 18a2에 대한 항체 및 그의 용도 |
CN111944048B (zh) * | 2019-05-16 | 2023-10-03 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
CA3141504A1 (en) * | 2019-05-24 | 2020-12-03 | Sanyou Biopharmaceuticals Co., Ltd. | Novel cldn18.2 binding molecule |
CN111978402B (zh) * | 2019-05-24 | 2022-06-28 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
EP3929214A4 (en) * | 2019-05-30 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR TARGETING CLAUDIN 18.2 |
CN110331199B (zh) * | 2019-06-28 | 2022-04-05 | 国家纳米科学中心 | 用于检测cldn18.2基因表达的分子探针及检测方法 |
WO2021003082A1 (en) * | 2019-07-03 | 2021-01-07 | Phanes Therapeutics, Inc. | Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof |
BR112022003147A2 (pt) * | 2019-08-20 | 2022-05-17 | Suzhou Transcenta Therapeutics Co Ltd | Novos anticorpos anti-cldn18.2 |
CN114981303B (zh) * | 2019-09-13 | 2024-01-23 | 安徽俊义医疗管理咨询有限公司 | 人源化抗Claudin18.2(CLDN18.2)抗体 |
CN112574307B (zh) * | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
BR112022008653A2 (pt) * | 2019-11-05 | 2022-07-19 | Lanova Medicines Ltd | Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco |
KR20220111308A (ko) | 2019-12-06 | 2022-08-09 | 소티오 바이오테크 에이.에스. | 인간화 cldn18.2 항체 |
WO2021115303A1 (zh) * | 2019-12-11 | 2021-06-17 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
CN114901365A (zh) | 2019-12-23 | 2022-08-12 | 斯迪安生物技术公司 | 肿瘤特异性密蛋白18.2抗体 |
CN113272332B (zh) * | 2020-01-03 | 2022-11-18 | 上海恺兴诊断技术有限公司 | 抗Claudin18.2的抗体及其应用 |
CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
AU2021220887A1 (en) * | 2020-02-10 | 2022-09-29 | Shanghai Escugen Biotechnology Co., Ltd. | CLDN18.2 antibody and use thereof |
CN115397856A (zh) * | 2020-03-30 | 2022-11-25 | 生物技术公司 | 靶向密蛋白-18.2的rna组合物 |
US20230331836A1 (en) * | 2020-05-25 | 2023-10-19 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-cldn18.2 antibodies and diagnostic uses thereof |
WO2021239026A1 (zh) * | 2020-05-29 | 2021-12-02 | 杭州邦顺制药有限公司 | 针对Claudin18.2的抗体及其用途 |
CN113854234B (zh) * | 2020-06-30 | 2023-09-08 | 江苏奥赛康生物医药有限公司 | 一种小鼠胰腺癌模型及其构建方法和应用 |
WO2022011531A1 (zh) * | 2020-07-14 | 2022-01-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
CN111705085B (zh) * | 2020-08-20 | 2020-12-25 | 北京百奥赛图基因生物技术有限公司 | 构建动物模型的方法及应用 |
WO2022100590A1 (zh) * | 2020-11-10 | 2022-05-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的adcc增强型人源化抗体及其应用 |
WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
CA3199830A1 (en) | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
US20240117035A1 (en) * | 2021-02-08 | 2024-04-11 | Shandong Boan Biotechnology Co., Ltd. | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors |
EP4347659A1 (en) * | 2021-05-31 | 2024-04-10 | Shijiazhuang Yiling Pharmaceutical Co., Ltd. | Monoclonal antibodies against cldn18.2 and fc-engineered versions thereof |
CN113687085A (zh) * | 2021-08-27 | 2021-11-23 | 复旦大学附属中山医院 | 一种评估实体肿瘤Claudin18.2蛋白表达的方法和应用 |
CN113788894B (zh) * | 2021-09-03 | 2022-08-05 | 深圳市先康达生命科学有限公司 | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 |
CN117897403A (zh) * | 2021-09-24 | 2024-04-16 | 盛禾(中国)生物制药有限公司 | 一种抗Claudin18.2抗体及其应用 |
CA3235119A1 (en) * | 2021-10-19 | 2023-04-27 | Mingjiu Chen | Antibodies binding cldn18.2 and uses thereof |
CN114836388A (zh) * | 2022-06-07 | 2022-08-02 | 江苏亲科生物研究中心有限公司 | Claudin18.2单克隆抗体及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007027867A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
CN101312989A (zh) * | 2005-11-24 | 2008-11-26 | 加尼梅德药物公司 | 用于治疗癌症的针对密蛋白-18的单克隆抗体 |
Family Cites Families (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5589579A (en) | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
WO2000077037A2 (en) | 1999-06-15 | 2000-12-21 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001004311A1 (en) | 1999-07-07 | 2001-01-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000073454A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000015796A2 (en) | 1998-09-16 | 2000-03-23 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
JP2001501447A (ja) | 1996-01-11 | 2001-02-06 | コリクサ コーポレイション | 乳癌の処置および診断のための組成物および方法 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030073129A1 (en) | 1998-09-01 | 2003-04-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030022298A1 (en) | 1997-09-15 | 2003-01-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20050196832A1 (en) | 1997-09-18 | 2005-09-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030008352A1 (en) | 1997-09-18 | 2003-01-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030027272A1 (en) | 1997-09-18 | 2003-02-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030166104A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030032103A1 (en) | 1997-09-18 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7160985B2 (en) | 1997-10-29 | 2007-01-09 | Genentech, Inc. | Pro180 polypeptide |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US20030040471A1 (en) | 1998-04-29 | 2003-02-27 | Watson James D. | Compositions isolated from skin cells and methods for their use |
US20030022835A1 (en) | 1998-04-29 | 2003-01-30 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
JP3428441B2 (ja) | 1998-05-15 | 2003-07-22 | エーザイ株式会社 | タイトジャンクション構成膜蛋白質クローディンファミリー |
US7319008B2 (en) | 1998-06-02 | 2008-01-15 | Genentech, Inc. | Nucleic acid underexpressed in melanoma |
US7351543B2 (en) | 1998-06-02 | 2008-04-01 | Genentech, Inc. | Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma |
JP2002517222A (ja) | 1998-06-11 | 2002-06-18 | スミスクライン ビーチャム コーポレーション | Gpr35a受容体 |
US7339033B2 (en) | 1998-06-26 | 2008-03-04 | Genentech, Inc. | Pro1481 |
EP1104486A4 (en) | 1998-08-04 | 2002-07-17 | Diadexus Llc | NEW METHOD FOR DIAGNOSIS, FOLLOW-UP, AND IMAGE OF LUNG CANCER |
US20050181478A1 (en) | 1998-09-01 | 2005-08-18 | Baker Kevin P. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
US7038019B2 (en) | 1998-09-01 | 2006-05-02 | Genentech, Inc. | Antibodies to PRO1410 |
US7041805B2 (en) | 1998-09-01 | 2006-05-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030082626A1 (en) | 1998-09-01 | 2003-05-01 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000015659A2 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
CA2345377A1 (en) * | 1998-10-06 | 2000-04-13 | Curagen Corporation | Novel secreted proteins and polynucleotides encoding them |
US7399834B2 (en) | 1998-10-07 | 2008-07-15 | Genentech, Inc. | Anti-PRO1558 antibodies |
AU1450900A (en) | 1998-10-21 | 2000-05-08 | Arch Development Corporation | Methods of treatment of type 2 diabetes |
US7026449B2 (en) | 1999-01-05 | 2006-04-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7465785B2 (en) | 1999-03-08 | 2008-12-16 | Genentech, Inc. | Polypeptide encoded by a nucleic acid over-expressed in melanoma |
KR20030002292A (ko) | 1999-03-08 | 2003-01-08 | 제넨테크, 인크. | 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산 |
JP2003531811A (ja) | 1999-03-08 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 血管形成及び心臓血管新生の促進又は阻害 |
US7507404B2 (en) | 1999-03-08 | 2009-03-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU764092B2 (en) | 1999-03-23 | 2003-08-07 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP2004507202A (ja) | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」 |
US20080286821A1 (en) | 1999-05-14 | 2008-11-20 | Eaton Dan L | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU3246100A (en) | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
AU2215300A (en) | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
PT1185648E (pt) | 1999-06-22 | 2007-06-29 | Genentech Inc | Métodos e composições para a inibição do crescimento de células neoplásicas. |
EP1208202A2 (en) | 1999-09-01 | 2002-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU1205901A (en) | 1999-10-14 | 2001-04-23 | Board Of Trustees Of The University Of Arkansas, The | Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof |
CA2496312A1 (en) | 1999-12-01 | 2001-06-07 | Kevin P. Baker | Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same |
US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
JP4280444B2 (ja) | 2000-01-06 | 2009-06-17 | ジェネンテック・インコーポレーテッド | 腫瘍性細胞成長阻害のための組成物及び方法 |
CA2396719A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | 22 human secreted proteins |
WO2001055326A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
CA2395295A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins and antibodies |
US20040018969A1 (en) | 2000-01-31 | 2004-01-29 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
WO2001062920A2 (en) | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
CA2747325A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2001260847A1 (en) | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
WO2002002621A2 (en) | 2000-06-30 | 2002-01-10 | Zymogenetics, Inc. | Mammalian secreted proteins |
AU2001284703B2 (en) | 2000-08-03 | 2007-03-22 | Therapeutic Human Polyclonals Inc. | Production of humanized antibodies in transgenic animals |
AU2001285047A1 (en) | 2000-08-16 | 2002-02-25 | Chiron Corporation | Human genes and gene expression products |
WO2002018576A2 (en) | 2000-08-28 | 2002-03-07 | Diadexus, Inc. | Compositions and methods relating to lung specific genes |
MXPA03002049A (es) | 2000-09-08 | 2003-07-24 | Schering Corp | Genes de mamiferos: reactivos y metodos relacionados. |
JP2004526411A (ja) | 2000-09-18 | 2004-09-02 | トマス・ジエフアーソン・ユニバーシテイ | 胃および食道癌細胞を同定および標的とするための組成物および方法 |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2440008A1 (en) | 2001-01-29 | 2002-08-29 | Phase-1 Molecular Toxicology, Inc. | Rat toxicologically relevant genes and uses thereof |
JP2004526441A (ja) | 2001-02-26 | 2004-09-02 | アリーナ・フアーマシユーチカルズ・インコーポレーテツド | 内因性および非内因性型ヒトgタンパク質共役受容体 |
US20030152939A1 (en) | 2001-04-09 | 2003-08-14 | Glennda Smithson | Novel secreted proteins and polynucleotides encoding them |
US20060084794A1 (en) | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2003000249A (ja) | 2001-05-10 | 2003-01-07 | Daiichi Fine Chemical Co Ltd | クローディンによるMT−MMPsを介したproMMP−2活性化 |
CA2449042A1 (en) | 2001-05-30 | 2002-12-27 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
JP2004533840A (ja) | 2001-07-06 | 2004-11-11 | ジェネンテック・インコーポレーテッド | ファージディスプレイによるpdzドメインリガンド |
CA2457424A1 (en) | 2001-08-03 | 2003-02-20 | Arbor Vita Corporation | Molecular interactions in cells |
US20030023042A1 (en) | 2001-12-06 | 2003-01-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
CA2379661A1 (en) | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
WO2003101283A2 (en) | 2002-06-04 | 2003-12-11 | Incyte Corporation | Diagnostics markers for lung cancer |
WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
BRPI0314814C1 (pt) | 2002-09-27 | 2021-07-27 | Xencor Inc | anticorpo compreendendo uma variante de fc |
NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
CA2505479A1 (en) | 2002-11-14 | 2004-06-03 | Arbor Vita Corporation | Molecular interactions in neurons |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1430902A1 (en) | 2002-12-20 | 2004-06-23 | Mondobiotech Laboratories Anstalt | Pharmaceutical composition of interferon gamma with molecular diagnostics for the improved treatment of asthma bronchiale |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
JP2007507243A (ja) | 2003-10-03 | 2007-03-29 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 遺伝子発現プロファイルおよび使用方法 |
DE10354601B3 (de) | 2003-11-21 | 2005-06-23 | Chiropro Gmbh | Gelenkprothese für Fingerglieder |
WO2005052182A2 (en) | 2003-11-26 | 2005-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method of analyzing plasma membrane protein content of cells |
US20080119412A1 (en) | 2003-12-23 | 2008-05-22 | Nono Inc. | Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins |
WO2005076939A2 (en) | 2004-02-09 | 2005-08-25 | University Of Kentucky Research Foundation | Assay and method for diagnosing and treating alzheimer’s disease |
WO2005082398A2 (en) | 2004-02-26 | 2005-09-09 | Ohio University | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells |
US20050255041A1 (en) | 2004-05-13 | 2005-11-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP2093569A3 (en) | 2004-05-21 | 2009-11-11 | The Institute for Systems Biology | Compositions and methods for quantification of serum glycoproteins |
WO2006023121A1 (en) | 2004-07-27 | 2006-03-02 | Ohio University | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in white adipose tissue (13) |
DE102004042822A1 (de) | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen |
FR2876705B1 (fr) | 2004-10-19 | 2008-12-12 | Biomerieux Sa | Procede pour le diagnostic d'une intolerance a l'aspirine |
US20070072175A1 (en) | 2005-05-13 | 2007-03-29 | Biogen Idec Ma Inc. | Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof |
CA2613482A1 (en) | 2005-07-01 | 2007-02-15 | Arbor Vita Corporation | Methods and compositions for diagnosis and treatment of influenza |
AU2006280321A1 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
JP5405110B2 (ja) | 2005-09-19 | 2014-02-05 | ベリデックス・エルエルシー | 原発不明がんの原発巣を同定するための方法および材料 |
AU2006304605A1 (en) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
NZ569957A (en) * | 2006-02-10 | 2012-03-30 | Genentech Inc | Anti-FGF19 antibodies and methods using same |
CA2647430A1 (en) | 2006-03-29 | 2007-10-11 | Genentech, Inc. | Diagnostics and treatments for tumors |
WO2008013954A2 (en) | 2006-07-27 | 2008-01-31 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
US8450057B2 (en) | 2006-08-14 | 2013-05-28 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
BRPI0716944A2 (pt) | 2006-09-19 | 2013-09-17 | Novartis Ag | biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf |
EP2087110A2 (en) | 2006-10-11 | 2009-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Influenza targets |
US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
WO2008073919A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
CA2677118A1 (en) | 2007-02-01 | 2008-08-07 | Veridex, Llc | Methods and materials for identifying the origin of a carcinoma of unknown primary origin |
EP2145902A3 (en) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
JP2010529966A (ja) | 2007-06-08 | 2010-09-02 | アシュラジェン インコーポレイテッド | 治療的介入の標的としてmiR−34によって調節される遺伝子および経路 |
WO2009015050A2 (en) | 2007-07-20 | 2009-01-29 | The Gov. Of The U.S.A. As Represented By The Secretary Of The Department Of Health & Human Services | Gene expression profile for predicting ovarian cancer patient survival |
WO2009035497A2 (en) | 2007-08-08 | 2009-03-19 | Savidge Tor C | Disease related cysteine modifications and uses thereof |
EP2036987A1 (en) | 2007-09-17 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | Molecular markers for tumor cell content in tissue samples |
WO2009047362A2 (en) | 2007-10-12 | 2009-04-16 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Method for opening tight junctions |
WO2009102367A2 (en) | 2007-11-19 | 2009-08-20 | The Regents Of The University Of Colorado | Tight junction protein modulators and uses thereof |
US20090304697A1 (en) | 2008-06-02 | 2009-12-10 | Nsabp Foundation, Inc. | Identification and use of prognostic and predictive markers in cancer treatment |
WO2009155609A1 (en) | 2008-06-20 | 2009-12-23 | Oklahoma Medical Research Foundation | IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE |
US20110190380A1 (en) | 2008-10-23 | 2011-08-04 | Elena Feinstein | Methods for delivery of sirna to bone marrow cells and uses thereof |
CN101381524A (zh) | 2008-10-24 | 2009-03-11 | 南开大学 | 单层氧化石墨与水溶性高分子增强复合材料 |
US20110286916A1 (en) | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
GB0904957D0 (en) | 2009-03-23 | 2009-05-06 | Univ Erasmus Medical Ct | Tumour gene profile |
US20120028816A1 (en) | 2009-03-31 | 2012-02-02 | Warren Stephen T | Methods and systems for screening for and diagnosing dna methylation associated with autism spectrum disorders |
CN101584860A (zh) * | 2009-04-27 | 2009-11-25 | 西安杰诺瓦生物科技有限公司 | 重组人Claudin18.2肿瘤疫苗及其制备方法 |
CA2776228A1 (en) | 2009-10-01 | 2011-04-07 | Chipdx Llc | System and method for classification of patients |
AU2010326066A1 (en) | 2009-12-01 | 2012-06-21 | Compendia Bioscience, Inc. | Classification of cancers |
CA2786940C (en) * | 2010-03-16 | 2019-09-24 | Biontech Ag | Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2 |
EP2366709A1 (en) | 2010-03-16 | 2011-09-21 | BioNTech AG | Tumor vaccination involving a humoral immune response against self-proteins |
US8945847B2 (en) | 2010-05-24 | 2015-02-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for ascertaining biosafety of an agent |
WO2011154139A2 (en) | 2010-06-07 | 2011-12-15 | Roche Diagnostics Gmbh | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
US8454385B2 (en) | 2010-06-22 | 2013-06-04 | John Mezzalingua Associates, LLC | Coaxial cable connector with strain relief clamp |
WO2012070014A2 (en) | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
JP5319023B2 (ja) | 2011-01-12 | 2013-10-16 | 森永乳業株式会社 | 免疫調節作用を有する乳を産生する食餌のスクリーニング法 |
DE102011005235B4 (de) | 2011-03-08 | 2017-05-24 | Sirs-Lab Gmbh | Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten |
EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY |
WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014025198A2 (ko) | 2012-08-09 | 2014-02-13 | 주식회사 한독 | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
WO2014025199A2 (ko) | 2012-08-09 | 2014-02-13 | 주식회사 한독 | 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
US20150299797A1 (en) | 2012-08-24 | 2015-10-22 | University Of Utah Research Foundation | Compositions and methods relating to blood-based biomarkers of breast cancer |
US20140073524A1 (en) | 2012-09-07 | 2014-03-13 | Institute For Systems Biology | Markers and methods for detecting posttraumatic stress disorder (ptsd) |
US9856532B2 (en) | 2012-09-07 | 2018-01-02 | Institute For Systems Biology | Markers and methods for detecting posttraumatic stress disorder (PTSD) |
-
2012
- 2012-05-09 WO PCT/EP2012/001991 patent/WO2013167153A1/en active Application Filing
-
2013
- 2013-05-06 SG SG11201406472WA patent/SG11201406472WA/en unknown
- 2013-05-06 SI SI201331647T patent/SI2847225T1/sl unknown
- 2013-05-06 LT LTEP13721596.8T patent/LT2847225T/lt unknown
- 2013-05-06 CA CA2869725A patent/CA2869725C/en active Active
- 2013-05-06 CN CN202210243984.0A patent/CN114573697A/zh active Pending
- 2013-05-06 RS RS20200006A patent/RS59868B1/sr unknown
- 2013-05-06 MX MX2014013542A patent/MX369740B/es active IP Right Grant
- 2013-05-06 KR KR1020237007205A patent/KR20230035697A/ko not_active Application Discontinuation
- 2013-05-06 BR BR112014026755A patent/BR112014026755B8/pt active IP Right Grant
- 2013-05-06 NZ NZ700823A patent/NZ700823A/en not_active IP Right Cessation
- 2013-05-06 PT PT137215968T patent/PT2847225T/pt unknown
- 2013-05-06 EP EP22152178.4A patent/EP4036119A1/en active Pending
- 2013-05-06 EP EP13721596.8A patent/EP2847225B1/en active Active
- 2013-05-06 RU RU2014149332A patent/RU2661772C2/ru active
- 2013-05-06 KR KR1020147031431A patent/KR102308812B1/ko active IP Right Grant
- 2013-05-06 US US14/397,244 patent/US9512232B2/en active Active
- 2013-05-06 EP EP19210903.1A patent/EP3666796A1/en not_active Withdrawn
- 2013-05-06 SG SG10201606048PA patent/SG10201606048PA/en unknown
- 2013-05-06 WO PCT/EP2013/001331 patent/WO2013167259A1/en active Application Filing
- 2013-05-06 ES ES13721596T patent/ES2763965T3/es active Active
- 2013-05-06 DK DK13721596.8T patent/DK2847225T3/da active
- 2013-05-06 JP JP2015510676A patent/JP6232646B2/ja active Active
- 2013-05-06 NZ NZ718280A patent/NZ718280A/en not_active IP Right Cessation
- 2013-05-06 KR KR1020217031155A patent/KR102506364B1/ko active IP Right Grant
- 2013-05-06 HU HUE13721596A patent/HUE049171T2/hu unknown
- 2013-05-06 CN CN201810016956.9A patent/CN108047331B/zh active Active
- 2013-05-06 PL PL13721596T patent/PL2847225T3/pl unknown
- 2013-05-06 UA UAA201711510A patent/UA123943C2/uk unknown
- 2013-05-06 AU AU2013258432A patent/AU2013258432B2/en active Active
- 2013-05-06 CN CN201380024247.0A patent/CN104321345B/zh active Active
- 2013-05-07 AR ARP130101567A patent/AR090973A1/es unknown
- 2013-06-05 UA UAA201413190A patent/UA116445C2/uk unknown
-
2014
- 2014-10-09 ZA ZA2014/07336A patent/ZA201407336B/en unknown
- 2014-10-22 IL IL235261A patent/IL235261B/en active IP Right Grant
-
2015
- 2015-03-23 HK HK15102925.9A patent/HK1202557A1/zh unknown
-
2016
- 2016-08-03 US US15/227,565 patent/US10053512B2/en active Active
-
2017
- 2017-08-16 AU AU2017216513A patent/AU2017216513B2/en active Active
- 2017-10-02 JP JP2017192778A patent/JP6514294B2/ja active Active
-
2018
- 2018-07-17 US US16/037,759 patent/US20180319891A1/en active Pending
-
2019
- 2019-04-11 JP JP2019075579A patent/JP6878491B2/ja active Active
- 2019-08-28 AU AU2019222874A patent/AU2019222874B2/en active Active
- 2019-12-30 HR HRP20192347TT patent/HRP20192347T1/hr unknown
-
2020
- 2020-01-08 CY CY20201100015T patent/CY1122676T1/el unknown
-
2021
- 2021-04-28 JP JP2021075743A patent/JP2021138700A/ja active Pending
-
2023
- 2023-05-17 JP JP2023081407A patent/JP2023109883A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007027867A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
CN101312989A (zh) * | 2005-11-24 | 2008-11-26 | 加尼梅德药物公司 | 用于治疗癌症的针对密蛋白-18的单克隆抗体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104321345B (zh) | 用于癌症诊断的针对密蛋白18.2的抗体 | |
CN104334580B (zh) | 抗sez6抗体及使用方法 | |
JP5328155B2 (ja) | Adam−9モジュレータ | |
KR101960004B1 (ko) | Cldn6 생체내 표적-지향된 항체를 이용하는 암 치료법 | |
JP5028635B2 (ja) | Fzd10に対する腫瘍標的化モノクローナル抗体とその使用 | |
MX2015002337A (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
TR201806936T4 (tr) | Anti-dll3 antikoru. | |
CN109988240A (zh) | 抗gpc-3抗体及其用途 | |
BR112020003694A2 (pt) | anticorpos úteis no diagnóstico do câncer | |
WO2021147954A1 (zh) | Semg2抗体及其用途 | |
NZ738493B2 (en) | Antibodies against claudin 18.2 useful in cancer diagnosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200624 Address after: Tokyo, Japan Co-patentee after: Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Univers Patentee after: Astellas Pharma Inc. Address before: Mainz, Germany Co-patentee before: Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Univers Patentee before: GANYMED PHARMACEUTICALS AG |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150128 Assignee: VENTANA MEDICAL SYSTEMS, Inc. Assignor: ASTELLAS PHARMA Inc.|Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Univers Contract record no.: X2022990000425 Denomination of invention: Antibodies against claudin 18.2 for cancer diagnosis Granted publication date: 20180330 License type: Common License Record date: 20220728 |
|
EE01 | Entry into force of recordation of patent licensing contract |